BIO Submits Comments Regarding DRAFT 2016 Letter to Issuers in the Federally-facilitated Marketplaces
<p>
The Biotechnology Industry Organization (BIO) is pleased to submit the following comments regarding the Center for Medicare and Medicaid Services (CMS) Center for Consumer Information and Insurance Oversight’s (CCIIO’s) “Draft 2016 Letter to Issuers in the Federally-facilitated Marketplaces” published on December 19, 2014 (the “Draft Letter”).</p>
The Biotechnology Industry Organization (BIO) is pleased to submit the following comments regarding the Center for Medicare and Medicaid Services (CMS) Center for Consumer Information and Insurance Oversight’s (CCIIO’s) “Draft 2016 Letter to Issuers in the Federally-facilitated Marketplaces” published on December 19, 2014 (the “Draft Letter”). While we acknowledge that CMS is working diligently to provide meaningful guidance to stakeholders, we find that the Agency’s reliance on a public comment period that is less than 30 days does not allow for thorough consideration by the public of all the proposals contained in this guidance. Thus, we ask that CMS return to at least a 30-day comment period in future years.
